its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Shares in the Ireland-based rare disease specialist fell sharply after news of the complete response letter (CRL ...

Hassan, who lives in Germany, has a genetic disease - junctional epidermolysis bullosa - that leaves his ... [for each form of EB] so we need formal clinical trials." But if they can make it ...

City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...